![](https://webarchive.library.unt.edu/eot2008/20081015073344im_/http://www.cancer.gov/images/spacer.gif) |
|
Phase IIB Randomized Study of Eflornithine (DFMO) and Sulindac in the Prevention of Colorectal Carcinoma in Patients With Previously Resected Colorectal Adenoma
Alternate Title Basic Trial Information Objectives Entry Criteria Expected Enrollment Outline Trial Contact Information Registry Information
Alternate Title
Eflornithine Plus Sulindac in Preventing Colorectal Cancer in Patients Who
Have Had Surgery to Remove Benign Colorectal Polyps
Basic Trial Information
![](https://webarchive.library.unt.edu/eot2008/20081015073344im_/http://www.cancer.gov/images/spacer.gif) |
Phase
![](https://webarchive.library.unt.edu/eot2008/20081015073344im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015073344im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015073344im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015073344im_/http://www.cancer.gov/images/spacer.gif) |
Type
![](https://webarchive.library.unt.edu/eot2008/20081015073344im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015073344im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015073344im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015073344im_/http://www.cancer.gov/images/spacer.gif) |
Status
![](https://webarchive.library.unt.edu/eot2008/20081015073344im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015073344im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015073344im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015073344im_/http://www.cancer.gov/images/spacer.gif) |
Age
![](https://webarchive.library.unt.edu/eot2008/20081015073344im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015073344im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015073344im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015073344im_/http://www.cancer.gov/images/spacer.gif) |
Sponsor
![](https://webarchive.library.unt.edu/eot2008/20081015073344im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015073344im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015073344im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015073344im_/http://www.cancer.gov/images/spacer.gif) |
Protocol IDs
![](https://webarchive.library.unt.edu/eot2008/20081015073344im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015073344im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015073344im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015073344im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015073344im_/http://www.cancer.gov/images/spacer.gif)
Phase II
![](https://webarchive.library.unt.edu/eot2008/20081015073344im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20081015073344im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015073344im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015073344im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015073344im_/http://www.cancer.gov/images/spacer.gif)
Prevention
![](https://webarchive.library.unt.edu/eot2008/20081015073344im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20081015073344im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015073344im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015073344im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015073344im_/http://www.cancer.gov/images/spacer.gif)
Closed
![](https://webarchive.library.unt.edu/eot2008/20081015073344im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20081015073344im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015073344im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015073344im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015073344im_/http://www.cancer.gov/images/spacer.gif)
40 to 80
![](https://webarchive.library.unt.edu/eot2008/20081015073344im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20081015073344im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015073344im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015073344im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015073344im_/http://www.cancer.gov/images/spacer.gif)
NCI
![](https://webarchive.library.unt.edu/eot2008/20081015073344im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20081015073344im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015073344im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015073344im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015073344im_/http://www.cancer.gov/images/spacer.gif)
UCIRVINE-97-05 NCI-P00-0150, NCT00005882
![](https://webarchive.library.unt.edu/eot2008/20081015073344im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20081015073344im_/http://www.cancer.gov/images/spacer.gif) |
|
Objectives - Compare the efficacy of eflornithine (DFMO) and sulindac vs placebo in modulating a panel of surrogate endpoint biomarkers (SEB) of particular relevance in colorectal neoplasia, including quantitative histopathology, uninduced apoptosis, proliferative (Ki67) and preneoplastic (CEA, sialyl-TN, p53, and bcl-2) features, and polyamine and PGE2 levels in patients with at least one previously resected colorectal adenoma.
- Determine the relationship between the modulation of SEB in flat mucosa and the development of interval incident colorectal adenomas in these patients.
Entry Criteria Disease Characteristics:
- At least 1 prior resected colorectal adenoma within the past 5 years
- No personal or family history of familial adenomatous polyposis
Prior/Concurrent Therapy:
Biologic therapy: Chemotherapy: - No concurrent chemotherapy
Endocrine therapy: - No concurrent corticosteroids
Radiotherapy: - No concurrent radiotherapy
Surgery: - See Disease Characteristics
Other: - No other concurrent nonsteroidal anti-inflammatories or
anticoagulants administered on a regular or predictable intermittent
basis
- No concurrent aspirin greater than 81 mg per day or 325 mg
twice a week for cardiovascular disease prophylaxis
- No concurrent calcium supplements greater than 500
mg/day
Patient Characteristics:
Age: Performance status: Life expectancy: Hematopoietic: - Hematocrit at least 35%
- WBC at least 4,000/mm3
- Platelet count at least 100,000/mm3
Hepatic: - Bilirubin no greater than 2.0 mg/dL
- AST and ALT no greater than 2 times normal
Renal: - Creatinine no greater than 1.5 mg/dL
- No greater than 1+ protein, 0-3 casts, and 0-5 WBCs and RBCs
in urine
Gastrointestinal: - No requirement for special diet or additives
- No diet that would preclude taking study medications
- No gastric or duodenal ulcer within the past year
- No inflammatory bowel disease
Other: - No more than 20 dB hearing loss for age at any
frequency
- No prior or concurrent invasive cancer within the past 5 years
except nonmelanomatous skin cancer, melanoma in situ, stage I
cervical cancer, stage I colon cancer, or stage 0 chronic lymphocytic
leukemia
- No severe metabolic disorder or other acute or chronic
diseases
- No history of or predisposition to abnormal wound healing or
repair
- No allergies to nonsteroidal anti-inflammatories or
eflornithine
- Not pregnant or nursing
- Fertile patients must use effective contraception
Expected Enrollment Approximately 240 patients (120 per treatment arm) will be accrued for this
study within 18 months. Outline This is a randomized, double-blind, placebo-controlled, multicenter
study. Patients are stratified according to aspirin use (yes vs no) and
participating center. Patients receive oral placebo daily for the first 4 weeks. Patients who
are compliant and take the placebo 5 to 7 days each week are randomized to one
of two treatment arms. - Arm I: Patients receive oral sulindac and oral eflornithine (DFMO)
daily.
- Arm II: Patients receive oral placebo daily.
Treatment continues for 3 years in the absence of disease progression or
unacceptable toxicity.
Trial Contact Information
Trial Lead Organizations Chao Family Comprehensive Cancer Center at University of California Irvine Medical Center ![](https://webarchive.library.unt.edu/eot2008/20081015073344im_/http://www.cancer.gov/images/spacer.gif) | ![](https://webarchive.library.unt.edu/eot2008/20081015073344im_/http://www.cancer.gov/images/spacer.gif) | ![](https://webarchive.library.unt.edu/eot2008/20081015073344im_/http://www.cancer.gov/images/spacer.gif) | Frank Meyskens, MD, FACP, Protocol chair | ![](https://webarchive.library.unt.edu/eot2008/20081015073344im_/http://www.cancer.gov/images/spacer.gif) | | ![](https://webarchive.library.unt.edu/eot2008/20081015073344im_/http://www.cancer.gov/images/spacer.gif) |
Registry Information | ![](https://webarchive.library.unt.edu/eot2008/20081015073344im_/http://www.cancer.gov/images/spacer.gif) | Official Title | | A Phase II Clinical Trial of a Randomized, Double-Blind, Placebo Controlled Clinical Trial of DFMO and Sulindac Against Various Endpoints of Colorectal Pathobiology in a Cohort of Individuals at Increased Risk of Colorectal Carcinoma | ![](https://webarchive.library.unt.edu/eot2008/20081015073344im_/http://www.cancer.gov/images/spacer.gif) | Trial Start Date | | 2000-06-27 | ![](https://webarchive.library.unt.edu/eot2008/20081015073344im_/http://www.cancer.gov/images/spacer.gif) | Registered in ClinicalTrials.gov | | NCT00005882 | ![](https://webarchive.library.unt.edu/eot2008/20081015073344im_/http://www.cancer.gov/images/spacer.gif) | Date Submitted to PDQ | | 2000-05-01 | ![](https://webarchive.library.unt.edu/eot2008/20081015073344im_/http://www.cancer.gov/images/spacer.gif) | Information Last Verified | | 2003-03-26 | ![](https://webarchive.library.unt.edu/eot2008/20081015073344im_/http://www.cancer.gov/images/spacer.gif) | NCI Grant/Contract Number | | P30-CA62203 |
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol. Back to Top |
![](images/spacer.gif) |